Pfizer: US, EU accept applications for lung cancer treatment
(CercleFinance.com) - The US and European health regulators have accepted to review Pfizer's dacomitinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), the drugmaker said on Wednesday.
In the US, the Food and Drug Administration has even granted a priority review for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations, it added.
The European Medicines Agency has also accepted the marketing authorization application for dacomitinib for the same indication, Pfizer added.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
In the US, the Food and Drug Administration has even granted a priority review for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations, it added.
The European Medicines Agency has also accepted the marketing authorization application for dacomitinib for the same indication, Pfizer added.
Copyright (c) 2018 CercleFinance.com. All rights reserved.